{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-oral/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"94667ccb-b451-5743-aeb8-44fbce6caf13","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 427c7b37-b517-4a75-be34-c974bcfd26aa --><h2>Changes</h2><!-- end field 427c7b37-b517-4a75-be34-c974bcfd26aa -->","summary":null,"htmlStringContent":"<!-- begin item 355c3619-da2c-4e01-85ad-825aecf143e2 --><!-- begin field e1dd5b02-fd81-48da-a46b-051eca0729a9 --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>July 2015 to October 2016</strong> — reviewed. Literature searches were conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been structural changes to the topic and changes to the recommendations have been updated in line with NICE guidance <em>Care of dying adults in the last days of life </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-oral/references/\">NICE, 2015</a>]. </p><!-- end field e1dd5b02-fd81-48da-a46b-051eca0729a9 --><!-- end item 355c3619-da2c-4e01-85ad-825aecf143e2 -->","topic":{"id":"ba62b1ab-ffea-5bce-8fd6-6127df66395a","topicId":"dc5a4c25-cbc0-4da8-9263-892c0ddb29be","topicName":"Palliative care - oral","slug":"palliative-care-oral","lastRevised":"Last revised in October 2018","chapters":[{"id":"92b78ff5-a7a3-533b-9fad-3812221a3e70","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e63cc0ed-d679-5b57-bd5d-a0fffc2bb1c5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0d446cc8-8026-59f2-8be3-a3df05f54690","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"94667ccb-b451-5743-aeb8-44fbce6caf13","slug":"changes","fullItemName":"Changes"},{"id":"d267c387-0c44-5636-b186-efd35314ddb7","slug":"update","fullItemName":"Update"}]},{"id":"b1959eca-8652-570a-bf43-e03f35359c72","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"190545c6-de91-566d-97ca-ec507ec5ffd5","slug":"goals","fullItemName":"Goals"},{"id":"51115a15-fe56-57ee-99b3-cdd5c4f1c6a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4d5ef3b4-1232-5943-8fad-b29aa5998488","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"80c55ca1-b9c4-5b9f-9bc7-c6c5fd42df42","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"909bc973-bd01-5f89-8719-11278e3eec78","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6f3efef7-3ed5-5013-9a70-606c9dbe0943","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"78d7fe5a-a1b6-58ed-9302-ad88f95d8db5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f6c72ae5-a1db-5d81-b680-40d5e677f0e7","slug":"causes","fullItemName":"Causes"},{"id":"c6626f56-2d11-59eb-aaa1-7df1a7759a57","slug":"oral-problems","fullItemName":"Oral problems"},{"id":"047eef6e-58db-5c3e-bbc9-a5b23171e78a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"efa65b1a-1a58-5453-b232-dcb7a4ad4533","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"87dda915-3779-5f4a-afd9-f77577bf772b","slug":"complications","fullItemName":"Complications"}]},{"id":"8d836099-7e31-5881-bb05-20f08d446d0b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b391498b-1e1b-5dcb-a663-5c2acc77475b","slug":"history","fullItemName":"History"},{"id":"b7bc660c-5027-59c4-b81e-daabd0aae4ef","slug":"examination","fullItemName":"Examination"},{"id":"01753f6e-7f5f-5eea-a4f5-860d02375047","slug":"investigations","fullItemName":"Investigations"}]},{"id":"b7921f28-c4d4-513c-9424-c072661841bd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8e4de9d8-84d5-5ccb-a53b-b45928ebc3e0","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"b1f750e8-79b4-5942-abd9-85bc539f3606","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"1fcf7fd1-2915-57d3-b741-40d617974983","slug":"dry-mouth","fullItemName":"Scenario: Dry mouth"},{"id":"89366510-b0a8-56fc-bf18-765bf712040e","slug":"oral-pain","fullItemName":"Scenario: Oral pain"},{"id":"dcda2b7f-7a28-5b54-81d7-74ca0a1293ac","slug":"oral-candida-infection","fullItemName":"Scenario: Oral candida infection"},{"id":"ceee9eeb-7174-5047-ae7d-904f58b5e2df","slug":"mouth-ulcers-mucositis","fullItemName":"Scenario: Mouth ulcers and mucositis"},{"id":"ceebbe2f-4f2d-5b69-8484-69a7b63d4155","slug":"halitosis-excessive-salivation-altered-taste","fullItemName":"Scenario: Halitosis, excessive salivation and altered taste"},{"id":"ae4a6023-826b-5bf3-8610-183b69c705c0","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"f953784c-8686-5a90-92cd-60d68dbd6845","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"26f08b6c-5b56-5782-8732-efb4b6e713af","slug":"topical-artificial-saliva-saliva-stimulant-products","fullItemName":"Topical artificial saliva and saliva stimulant products"},{"id":"96912fd4-a2b4-50f9-86ed-8bb2e45463c5","slug":"oral-pilocarpine","fullItemName":"Oral pilocarpine"},{"id":"c8127148-af88-5ea4-860a-50fcf5aac054","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"fff90e93-10dd-553e-82f8-0dfd41609a37","slug":"oral-antifungals","fullItemName":"Oral antifungals"},{"id":"065c7442-bd39-51f9-a981-cdaccb1ba40c","slug":"chlorhexidine","fullItemName":"Chlorhexidine"},{"id":"94720495-b83a-5896-aad4-6fe5a74a5f78","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"1c9aa8fa-0094-5e8d-9745-40f1deb0a4bd","slug":"antivirals","fullItemName":"Antivirals"},{"id":"ccf55d3d-9d86-5178-b7de-efe3554f8ad1","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"e8b50dff-617d-541c-8f6c-32d1cc172ad5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"49c2337d-75af-5e94-a422-dce3f68c22c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"87ab81b8-3331-56e9-97da-8ccde09bb168","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fcdbc4c2-0265-55de-83ef-890d4a2eb6e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5e11b2-f829-5c8a-ba4e-4bd0c552209e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a6cc052-004c-5f0c-83f8-f04899c06292","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e1ee9217-75fd-57a2-8e67-0f9c468e36c9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a6d40f6b-b733-5a56-8b81-ff55062d9bcb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d446cc8-8026-59f2-8be3-a3df05f54690","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"2a47816d-aa53-5f21-8887-849237595c3f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 6c3fcb25-0884-4243-807e-a17842b4bbc7 --><h3>Previous changes</h3><!-- end field 6c3fcb25-0884-4243-807e-a17842b4bbc7 -->","summary":null,"htmlStringContent":"<!-- begin item 9af8fdff-bf8f-41a7-862b-49cb5ff7ac51 --><!-- begin field c440844e-9c4b-43b4-819a-2615cf9f6867 --><p><strong>July 2015 </strong>— topic title changed to reflect broader topic coverage than specifically cancer care.</p><p><strong>April 2015 </strong>—<strong> </strong>minor update. Link inserted.</p><p><strong>December 2013 </strong>— minor update. Text updated to reflect that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has suspended the marketing authorisation for oral ketoconazole, and it should not be prescribed for the treatment of fungal infections.</p><p><strong>August 2013 </strong>— minor update to the text to reflect recent guidance from the European Medicines Agency regarding the use of oral ketoconazole.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic medicines website (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"824540c9-bd49-4520-ac5e-a98c0161d1c0\">www.medicines.org.uk</a>) have been updated.</p><p><strong>November 2012 </strong>— reviewed. A literature search was conducted in August 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>February 2011 </strong>— topic structure revised to ensure consistency across CKS topics — no changes to clinical recommendations have been made.</p><p><strong>December 2009 </strong>— minor update. Xerotin<sup>®</sup>, an artificial saliva spray, is now listed in the Appliances section of the Drug Tariff, so can be prescribed on from FP10. Prescription added. Issued in December 2009.</p><p><strong>August 2009 </strong>— minor update. Triamcinolone in an adhesive paste (Adcortyl in Orabase<sup>®</sup>) is no longer available in either the 5 gram or the 10 gram pack size. Prescription removed. Issued in August 2009.</p><p><strong>April 2009 </strong>— minor update. Triamcinolone in an adhesive paste (Adcortyl in Orabase<sup>®</sup>) is no longer available in the 10 gram pack size. The 5 gram over-the-counter pack size is still available. Issued in May 2009.</p><p><strong>October 2008 </strong>— minor update. Quench Pharma Ltd. are now distributing BioXtra<sup>®</sup>gel. Text and prescriptions reinstated. Issued in October 2008.</p><p><strong>August 2008 </strong>— minor update. BioXtra<sup>®</sup>gel and nystatin pastilles discontinued; prescriptions removed and text amended. Issued in August 2008.</p><p><strong>January to April 2007 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.There have been no major changes to the recommendations. The primary care management of oral problems has been described in detail.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>June 2005 </strong>— minor update to include topical artificial saliva products containing lactoperoxidase. Issued in July 2005.</p><p><strong>February 2004 </strong>— written. Validated in March 2004 and issued in June 2004.</p><!-- end field c440844e-9c4b-43b4-819a-2615cf9f6867 --><!-- end item 9af8fdff-bf8f-41a7-862b-49cb5ff7ac51 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}